mRNA Nanoparticles Trigger Liver Regeneration Through Partial Reprogramming
Liver-targeted OSKM mRNA delivery induces regenerative progenitor cells and enhances recovery from acute liver injury in mice.
Summary
Partial reprogramming briefly activates the Yamanaka factors (OSKM) to promote cellular plasticity. In genetically engineered mice, three days of OSKM induction caused liver cells to lose mature features and generated two progenitor-like populations, with no overt short-term liver toxicity and limited injury-associated immune activation. After acetaminophen injury, OSKM induction reduced dead tissue at four days despite comparable damage at 24 hours, supporting faster repair. The researchers also developed liver-targeted lipid nanoparticles carrying OSKM messenger RNA. This transient, non-viral approach induced dedifferentiation and Sox9-positive progenitor-like cells and was associated with enhanced regeneration. The findings support further preclinical investigation, but do not establish human efficacy or long-term safety.
Detailed Summary
Partial reprogramming uses the Yamanaka factors Oct4, Sox2, Klf4, and c-Myc (OSKM) to induce cellular plasticity. Transgenic and viral delivery approaches raise concerns about prolonged expression, and the source cites reports of rapid liver and intestinal failure under strong OSKM induction. This study investigated whether brief, carefully dosed induction could promote liver repair and whether liver-targeted messenger RNA delivery could provide a transient, non-viral alternative.
The researchers gave doxycycline-inducible OSKM mice a low-dose regimen of 0.15 mg/mL doxycycline with 5% sucrose. Three-day induction produced no observed weight loss or ALT/AST elevation and minimal cleaved caspase-3 activity; histology showed no fibrosis or architectural abnormalities through day 4. Hepatocytes nevertheless lost mature markers and glycogen stores, progressing through Oct4-negative/Hnf4α-high, transitional, and Oct4-high/Hnf4α-negative states. Ki-67 and BrdU labeling indicated increased proliferation, accompanied by more diploid and fewer octoploid hepatocytes. In cultured hepatocytes, the Oct4-high/Hnf4α-negative population diminished within 48 hours after doxycycline withdrawal, suggesting reversibility rather than demonstrating complete disappearance.
For injury experiments, mice received sublethal or lethal acetaminophen doses of 300 or 500 mg/kg, followed by three days of OSKM induction. After 500 mg/kg, treated mice had less necrosis and fewer TUNEL-positive cells at 96 hours. Necrosis was comparable at 24 hours, supporting accelerated repair rather than reduced initial damage. The source also reports lower 4-HNE staining. Reduced cleaved caspase-3 was assessed separately at 48 hours after the 300 mg/kg dose and should not be assigned to the lethal-dose, 96-hour measurements.
Single-nucleus RNA sequencing identified two OSKM-induced liver progenitor-like cell populations, LPLC1 and LPLC2, arising without injury and with limited activation of injury-associated immune responses. One population resembled injury-induced LPLCs observed in acetaminophen-injured mouse and human livers. The supplied excerpt does not provide sequencing counts, population fold changes, or detailed signature-scoring results.
The researchers also established liver-targeted lipid nanoparticles carrying nucleoside-modified OSKM mRNA. This approach induced hepatocyte dedifferentiation and Sox9-positive LPLC-like cells and was associated with enhanced regeneration after acetaminophen injury. It supports transient mRNA delivery as a potential regenerative strategy, rather than establishing clinical efficacy or superior safety.
The supplied figures report small samples for several experiments, including n = 3 and n = 6. Short-term tolerability does not establish long-term safety, and the excerpt does not provide enough information to assess tumor-risk follow-up or lineage-tracing methods. Human efficacy and clinical dosing are not established by the supplied evidence.
Key Findings
- A 3-day low-dose OSKM pulse (0.15 mg/mL doxycycline) caused no observed weight loss or ALT/AST rise, minimal cleaved caspase-3 activity, and no fibrosis through day 4
- OSKM induction produced graded hepatocyte dedifferentiation, with reduced glycogen, higher Ki-67/BrdU proliferation, and fewer octoploid and more diploid hepatocytes
- After 500 mg/kg APAP, OSKM-induced mice had less necrosis and fewer TUNEL-positive cells at 96 hours despite comparable necrosis at 24 hours, supporting accelerated repair
- Reduced cleaved caspase-3 was assessed at 48 hours after 300 mg/kg APAP, separately from the lethal-dose, 96-hour necrosis and TUNEL measurements
- OSKM induction generated liver progenitor-like cells without injury and with limited activation of injury-associated immune responses
- Single-nucleus RNA sequencing identified two LPLC populations; one resembled injury-induced LPLCs observed in acetaminophen-injured mouse and human livers
- Liver-targeted OSKM mRNA-LNPs induced hepatocyte dedifferentiation and Sox9-positive LPLC-like cells and were associated with improved regeneration after APAP injury
Methodology
The study used doxycycline-inducible OSKM mice with homozygous 4F and rtTA alleles and a low-dose regimen of 0.15 mg/mL doxycycline with 5% sucrose. Injury experiments used intraperitoneal APAP at 300 or 500 mg/kg after a 12-hour fast, followed immediately by doxycycline treatment for 3 days. Readouts included histology, immunofluorescence, immunoblotting, TUNEL, serum ALT/AST, proliferation markers, hepatocyte ploidy, and primary-hepatocyte culture experiments. The source also reports single-nucleus RNA sequencing and a liver-targeted nucleoside-modified OSKM mRNA-LNP delivery strategy. Specific displayed experiments used n = 3 or n = 6, and Figure 1L specifies two-way ANOVA. The supplied excerpt does not provide the sequencing sample count or detailed computational methods.
Study Limitations
This is preclinical evidence, with small samples in several displayed experiments (n = 3 or n = 6). The detailed repair-kinetics results supplied here concern genetically inducible OSKM mice, while the abstract describes the mRNA-LNP benefit as associated with enhanced regeneration. Short-term tolerability does not establish long-term safety. The supplied excerpt does not establish human efficacy or dosing, provide tumor-risk follow-up, or allow assessment of lineage-tracing methods. Conflicts of interest were not available in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
